What Crossject does

Crossject is a French specialty pharmaceutical company headquartered in Dijon, France, that develops and commercializes emergency medicines delivered through its proprietary ZENEO needle-free auto-injector platform. Listed on Euronext Growth Paris since February 2014 under ticker ALCJ, the company targets three core emergency indications: severe allergic reactions (anaphylaxis) via ZENEO Epinephrine, prolonged epileptic seizures via ZEPIZURE (currently under FDA review), and acute adrenal crisis via ET-801. Its addressable patient populations include the approximately 65 million people globally living with epilepsy (40% refractory), the ~5 per 10,000 prevalence of acute adrenal crisis in the US and Europe, and the broad at-risk population for anaphylaxis. The core technology — a needle-free, pre-filled, single-use auto-injector — eliminates needles in time-critical administration, with the company citing speed, reliability, safety, and ease of use as its functional differentiators versus conventional needle-based auto-injectors.

The business model is a platform-plus-products specialty pharma approach: ZENEO serves as the reusable delivery device across multiple drug products, with revenue expected from pharmaceutical product sales once regulatory approvals are secured. ZEPIZURE is being advanced with substantial non-dilutive support from BARDA ($43.3 million funding increase) targeting potential emergency use authorization. The company is preparing for US commercial launch in 2026-2027 and has built US infrastructure including the wholly-owned CROSSJECT USA subsidiary, a VP US Business, a US Chief Medical Officer, and a strategic partnership with Eton Pharmaceuticals for US hospital distribution of ET-801. Additional capital has been raised through €6.9 million France 2030 public funding, €12 million Heights Capital Management bonds, €5.7 million capital increase with Gemmes Venture and Vatel Capital, €5 million Vatel Capital convertible bonds, and a €15 million equity/warrant issuance in June 2026.

As of mid-2025 the company reported 51-100 employees (with 160+ projected through 2026), an H1 2025 net loss of €4.9 million (improved from €6.4 million), and remains pre-commercial with no disclosed product revenue. The company has stated a long-term commercial target of approximately €1 billion in annual sales for ZENEO Epinephrine by 2032, contingent on regulatory approval, commercial launch execution, and US market penetration.

Name

Crossject

Legal name

CROSSJECT SA

Website

https://crossject.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

Crossject is a French specialty pharmaceutical company developing needle-free auto-injector (ZENEO) products for emergency medications targeting epileptic seizures, adrenal crisis, and severe allergic reactions, with US commercial launch planned for 2026-2027.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceutical Drug Delivery Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC)

Keywords

• Needle-free injection
• Emergency pharmaceuticals
• Auto-injector devices
• Drug delivery platform
• Specialty pharma products

Headquarters

HQ city

Dijon

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: CROSSJECT is a specialty pharmaceutical company developing emergency medicines based on its ZENEO needle-free auto-injector platform. The company is working toward regulatory approval and commercial launch, with expected sales of around EUR 1 billion by 2032.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Crossject develops and manufactures ZENEO®, a proprietary needle-free, pre-filled, single-use auto-injector platform designed for rapid delivery of emergency medications in life-threatening situations. The company builds a portfolio of emergency pharmaceutical products on top of this platform, including treatments for epileptic seizures, adrenal crises, and severe allergic reactions (anaphylaxis).

Product overview

CROSSJECT is a specialty pharmaceutical company developing emergency medicines based on its ZENEO® needle-free auto-injector platform. The company operates a platform-plus-products model where ZENEO® serves as the core technology enabling needle-free drug delivery across multiple therapeutic applications. The product portfolio includes ZENEO® Epinephrine for severe allergic reactions, ZEPIZURE® for epileptic seizures currently under FDA review, and ET-801 for adrenal insufficiency crises developed through partnership with Eton Pharmaceuticals. The platform is designed to provide safe, reliable, needle-free emergency treatment for life-threatening situations.

Differentiator

Problem solved

Functional benefit

Brands

• ZENEO®: Needle-free, pre-filled, single-use auto-injector platform for emergency medication delivery in life-threatening situations including epileptic seizures, adrenal crisis, and allergic shock
• ET-801
• ZEPIZURE®

Products and services

• ZENEO® Needle-Free Auto-Injector Platform A needle-free, pre-filled, single-use auto-injector platform for rapid, reliable delivery of emergency medications in critical situations, intended for healthcare providers, patients, and emergency responders.
• ZENEO® Epinephrine Needle-free epinephrine auto-injector for emergency treatment of severe allergic reactions (anaphylaxis) and allergic shock, enabling immediate administration without a needle.
• ZEPIZURE® Emergency medication built on the ZENEO® platform for rapid treatment of prolonged epileptic seizures (including refractory seizures), currently pursuing regulatory approval in the United States.
• ET-801 Ready-to-use hydrocortisone formulation developed in partnership with Eton Pharmaceuticals for treating adrenal insufficiency crises in the U.S. hospital market.

Quantifiable outcome

• Expected sales of around EUR 1 billion by 2032
• +1 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Eton PharmaceuticalscoreStrategic or Co-development Partner · 1 March 2025CROSSJECT partnered with Eton Pharmaceuticals in March 2025 to develop and commercialize ET-801, a ready-to-use hydrocortisone formulation for treating adrenal insufficiency crises in the US hospital market. The partnership leverages Eton's expertise in the US hospital market for commercial distribution.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• SHL Medical: SHL Medical is a leading developer and manufacturer of advanced auto-injector devices used by pharma partners to deliver injectable drugs. It is the most direct comparable to Crossject's ZENEO platform, competing for the same pharmaceutical partnership and combination-product opportunities across emergency and chronic injectable therapies.
• Antares Pharma (Halozyme): Antares Pharma, acquired by Halozyme, pioneered commercial-scale auto-injector technology (Vibex, Sumavel DosePro) used by pharma partners across multiple therapeutic areas. Its device-platform-plus-partner business model closely mirrors Crossject's ZENEO strategy and serves as the most directly comparable public-market benchmark.
• Ypsomed: Ypsomed is a Swiss-based medical device company specializing in injection and infusion systems, including proprietary auto-injector platforms for pharmaceutical partners. It is a direct platform peer in the device-plus-pharma-partnership model that competes for the same combination-product and self-injection opportunities as Crossject.
• kaléo (Auvi-Q): kaléo manufactures Auvi-Q, a compact epinephrine auto-injector that competes directly in the same anaphylaxis rescue market Crossject is targeting with ZENEO Epinephrine. It is the principal non-EpiPen competitor in US emergency epinephrine and is the most direct commercial competitor for ZENEO Epinephrine.

Broad incumbents

• West Pharmaceutical Services: West Pharmaceutical Services is a global leader in drug delivery components and containment systems, including elastomer components for injectable drug delivery. As a much larger incumbent, it overlaps with Crossject in the injectable drug-delivery supply chain across pharmaceutical customers using auto-injectors, prefilled syringes, and similar combination products.
• Becton, Dickinson and Company (BD): BD is a global medical technology company with a large Medical Delivery Solutions segment covering syringes, needles, and injection devices. While much broader than Crossject, BD operates in the same injection device space and serves overlapping pharmaceutical and emergency-medicine customers with both prefilled syringe and auto-injector offerings.
• Viatris (EpiPen): Viatris (formerly Mylan) manufactures EpiPen, the dominant epinephrine auto-injector globally. As the incumbent in Crossject's primary commercial target (anaphylaxis rescue), it defines the market share and pricing environment the ZENEO Epinephrine launch must disrupt.
• Halozyme Therapeutics: Halozyme Therapeutics acquired Antares Pharma to add a commercial-scale auto-injector platform to its drug-delivery franchise. Its broader ENHANZE drug-delivery technology plus Antares device assets makes it a large-cap public-market comparable for a platform-based, partnership-driven drug delivery strategy.

Emerging players

• Emergent BioSolutions: Emergent BioSolutions develops and supplies emergency medical countermeasures including NARCAN (naloxone) and other acute-care therapeutics. It overlaps with Crossject across the emergency-medicine franchise, biodefense procurement channels (BARDA), and the strategic focus on rapid, single-use rescue therapies.
• Adamis Pharmaceuticals (USL): Adamis Pharmaceuticals (recently acquired by USL) commercialized Symjepi, a pre-filled syringe epinephrine product that competes in the same emergency anaphylaxis category Crossject is targeting. It represents the small-cap, single-product competitor profile with comparable regulatory and US commercialization dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/crossject_?lang=fr
• YouTubeyoutube.com/channel/UC0a_enJsu3rE19iayE8dMbA
• LinkedInlinkedin.com/company/crossject

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crossject